Generic Industry Not Sold On Benefits Of FDA Emerging Technology Program
FDA’s calls for more generic industry participation in its Emerging Technology Program fell on deaf ears at recent meeting, with several complaining about the costs and value of investing in new manufacturing technologies.
You may also be interested in...
Makers of brand pharmaceuticals focused on scope issues and the definition of terms in their comments on the US FDA's draft continuous manufacturing guidance, while makers of generic drugs raised concerns about cost and lack of benefit.
As pharmaceutical companies begin taking advantage of continuous manufacturing, they are realizing how it can transform an industry rooted in batch processing. Now they have drafted a survival guide.